Search This Blog

Tuesday, January 3, 2023

Jasper: Positive Data in Phase I/II Trial of Treatment in Sickle Cell, Beta Thalassemia

 

  • All three sickle cell disease participants treated with briquilimab successfully engrafted with neutrophil engraftment within 12-16 days

  • First two participants with peripheral blood chimerism at 60 days after allogeneic stem cell transplant achieved 100% donor myeloid chimerism

  • First participant treated has a total hemoglobin level of 13.3 g/dL at five months follow up, increased from 8-9 g/dL at baseline

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.